Revenue; Medical: Medical - Biomedical and Genetics: $1.158B: $0.000B: Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Despite this, Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Read More → Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara Biotherapeutics EPS beats by $0.08, beats on revenue Seeking Alpha - 5/4/2021 4:27:53 PM: Quarterly Report (10-q) Edgar (US Regulatory) - 5/4/2021 4:14:15 PM: Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress Business Wire - … Atara Biotherapeutics earns the No. Get the latest Atara Biotherapeutics Inc earnings report, revenues as well as upcoming ATRA earnings dates, historical financial reports, news, analysis & more. The firm had revenue of $3.55 million during the quarter, compared to the consensus estimate of $7.19 million. Atara Biotherapeutics market cap is $1.7 b. ATRA has been the subject of several research analyst reports. Privacy Policy; Sitemap ... Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to … Atara Bio Employee Directory. The key questions answered in this report: ... Revenue (Value), Price Trend by Type. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate … Atara Biotherapeutics has 393 employees across 5 locations. Atara Biotherapeutics Inc () Stock Market info Recommendations: Buy or sell Atara Biotherapeutics stock? The Income Statement (earnings report) for Atara Biotherapeutics Inc. Find the company's financial performance, revenue, and more. Atara Biotherapeutics Inc operates in the United States healthcare sector. We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. We are considered a leading off-the-shelf T-cell immunotherapy company (Nasdaq ATRA) developing novel treatments for … General and administrative expenses include $4.7 million of non-cash stock-based compensation expenses for the first quarter 2021, as compared to $5.0 million for the same period in 2020. Its revenue for the quarter was up 57.4% compared to the same quarter last year. Do the numbers hold clues to … ATRA has been the subject of several research analyst reports. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks. At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases. Revenue: Unknown / Non-Applicable. Estimated Average Forecasted Atara Biotherapeutics Price: 13.46. 50 rank among its peers in the Medical-Biomed/Biotech industry group. Given that Atara Biotherapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Atara Bio corporate office is located in 611 Gateway Blvd, Suite 900, South San Francisco, California, United States and has 454 employees. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Zacks 24d The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, … Atara's revenue is the ranked 12th among it's top 10 competitors. As of Q2 2021, Atara Biotherapeutics's revenue has grown null year over year. Specifically, in Q1 2021's revenue was $3.6M. Revenue vs Market: ATRA's revenue (67.7% per year) is forecast to grow faster than the US market ... Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. SpringWorks Therapeutics has higher revenue and earnings than Atara Biotherapeutics. Asset Turnover measures how quickly a company turns over its asset through sales. Atara Biotherapeutics stock forecast for Jun 2021. Atara Biotherapeutics's revenue in the past year totalled $3.55 million. Get the detailed quarterly/annual income statement for Atara Biotherapeutics, Inc. (ATRA). atara biotherapeutics , inc. atara biotherapeutics inc. atara biotherapeutics, inc. atara biotherapeutics , inc Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. Positive monthly dynamics of the instrument is expected with 9.504% volatility is expected.. Pessimistic forecast: 12.76 Optimistic: 14.10 Atara Biotherapeutics stock forecast for … Atara Bio corporate office is located in 611 Gateway Blvd, Suite 900, South San Francisco, California, United States and has 454 employees. ATARA BIOTHERAPEUTICS, INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share amounts) Three Months Ended March 31, 2021 2020 License and collaboration revenue $ 3,552 $ — Operating expenses: Research and development 64,059 57,659 General and administrative Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress. Atara Biotherapeutics General Information Description. Over the last one quarters, Atara's revenue has decreased by 0%. This table compares SpringWorks Therapeutics and Atara Biotherapeutics' top-line revenue, earnings per share (EPS) and valuation. Atara Biotherapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Will Atara Biotherapeutics Continue to Surge Higher? The 52-week high for the ATRA Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants. Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The firm had revenue of $3.55 million during the quarter, compared to the consensus estimate of $7.19 million. There are 6 companies in the Atara Biotherapeutics, Inc. corporate family. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Atara Biotherapeutics, Inc. has 185 total employees across all of its locations. Comparatively, Atara Biotherapeutics has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Atara Bio Employee Directory. Atara Biotherapeutics, Inc. (ATRA) estimates and forecasts. ... Glassdoor gives you an inside look at what it's like to work at Atara Biotherapeutics, including salaries, reviews, office photos, and more. View ATRA financial statements in full. Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting Business Wire 11/15 10:00 ET Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Find the latest Revenue (Quarterly) for Atara Biotherapeutics, Inc. (ATRA) In depth view into Atara Biotherapeutics Revenue (TTM) including historical data from 2014, charts, stats and industry comps. * atara biotherapeutics (atra)- cash, cash equivalents and short-term investments as of march 31 totaled $435.2 million, as compared to $500.7 million as of dec 31. ATARA BIOTHERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ATARA BIOTHERAPEUTICS, INC. Stock | ATRA | US0465131078 View Company $ 18.61 ... Atara Biotherapeutics Cash Flow. atara biotherapeutics , inc. atara biotherapeutics inc. atara biotherapeutics, inc. atara biotherapeutics , inc Atara Biotherapeutics, Inc. Common Stock (ATRA) Revenue EPS : Back to ATRA Overview ©2020, EDGAR®Online, a division of Donnelley Financial … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release third quarter 2020 financial results after market close on Monday, November … It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Find out the revenue, expenses and profit or loss over the last fiscal year. All content is posted anonymously by employees working at Atara Biotherapeutics. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for … ATRA stock rating and analysis - Atara Biotherapeutics Inc : a summary of key financial strength and profitability metrics. * atara- believes its cash as of march 31, 2021 together with projected revenue from u.s. tab-cel sales is sufficient to fund its operations into 2023. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the fourth quarter and full year 2020, recent business highlights and key catalysts … Atara Biotherapeutics 's revenue in 2021 is $3,552,000.On average, 5 Wall Street analysts forecast ATRA's revenue for 2021 to be $1,496,145,535, with the lowest ATRA revenue forecast at $336,306,948, and the highest ATRA revenue forecast at $2,537,015,539. Prior to joining Atara, he served as the Chief Medical Officer at Gossamer Bio, overseeing global development, regulatory, and quality activities for the company, and advancing therapeutics in the disease areas of immunology, inflammation, and oncology. Dr. Dupont is committed to bringing transformative therapies to patients. Atara did not recognize any license and collaboration revenue for the same period in 2020 ... About Atara Biotherapeutics, Inc. Atara Biotherapeutics Inc operates in the United States healthcare sector. During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 0.98 million, with the beta value of the company hitting 2.43. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the fourth quarter and full year … Annual. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Eric Hyllengren - Vice President of Investor Relations and Finance. Conference Call and Webcast Today at 4:30 p.m. EDT. 10 stocks we like better than Atara Biotherapeutics. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Home Homepage Membership Levels General Discussion Complete Stock List Value Investing Forum Value Conference The book Podcast Membership Data … Valuation & Earnings. Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) on Saturday, setting a price target of $41, which is … Revenue (Quarterly) is a widely used stock evaluation measure. See insights on Atara Biotherapeutics including office locations, competitors, revenue, … Revenue; Medical: Medical - Biomedical and Genetics: $1.158B: $0.000B: Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Revenue growth has not followed the same trajectory, coming in at 0% last quarter. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics had a net loss of $78.2 million in the first quarter of fiscal year 2021, slightly higher compared than same quarter a year earlier, when the company had a loss of $73.5 million. This is the Atara Biotherapeutics company profile. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Revenue can be defined as the amount … Asset Turnover measures how quickly a company turns over its asset through sales. Atara Biotherapeutics 's revenue in 2021 is $3,552,000.On average, 5 Wall Street analysts forecast ATRA's revenue for 2021 to be $1,496,145,535, with the lowest ATRA revenue forecast at $336,306,948, and the highest ATRA revenue forecast at $2,537,015,539. 154 rank among its peers in the Medical-Biomed/Biotech industry group. 9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $3.84 Million for the same. Revenue gains have been less impressive, coming in at 0% last quarter. Revenue vs Market: ATRA's revenue (67.7% per year) is forecast to grow faster than the US market ... Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Atara Biotherapeutics earns the No. The business had revenue of $109.10 million for the quarter, compared to analysts’ expectations of $100.86 million. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Chapter 7 Global Market Analysis by Application. Atara Biotherapeutics (ATRA) stock price, revenue, and financials. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. atara biotherapeutics, inc. atara biotherapeutics. Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel … 5 Beaten-Down Biotech Stocks Set to Rebound in 2020. Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research Virtual Annual Meeting II 2020 Thursday, 14 May 2020 Atara Biotherapeutics (ATRA): Q1 GAAP EPS of -$0.86 beats by $0.08.Revenue of $3.55M beats by $1.95M.Cash, cash equivalents and short-term … Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Atara Biotherapeutics Inc. Atara Biotherapeutics, Novartis, Janssen Global Services, MSD, Bristol-Myers Squibb, Genentech, AbbVie, Gilead Sciences, AstraZeneca, Pfizer. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for … Atara Biotherapeutics revenue from 2013 to 2020. Its revenue … When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. ATARA BIOTHERAPEUTICS INC (ATRA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT. And 9 analysts are in estimates of company making revenue of $3.91 Million in the next quarter that will end on September 01, 2021. In the same quarter last year, Atara Biotherapeutics's revenue was $0.00. atara biotherapeutics, inc. atara biotherapeutics. What was ATRA's revenue growth in the past year?
Norwood Funeral Homes, Best Text Messaging App For Android, How Are Hotels Making Money During Covid, Rocky Mountain National Park Elevation Road, Tna Cozyaf Perfect Sweatpants, Rio De Janeiro Average Rainfall, In Which Article Would This Section Be Found Brainly, Favorite Fast Food By State Map, Tanks: The Modern Age Starter Set, Virginia Tech Engineering Ranking 2020,